© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
A payer and community physician raise attention to limitations surrounding measures for screening and treating atopic dermatitis.
November 19th 2021
An overview of what has been learned over time that can help dermatologists and other community physicians appropriately identify signs of atopic dermatitis in children and adults.
December 3rd 2021
December 6th 2021
The impact atopic dermatitis and associated comorbidities have on patients with the condition, as well as family members.
Indirect costs associated with atopic dermatitis, and the financial burden associated with delayed treatment initiation or inappropriate therapy.
Considerations for quality measures established for atopic dermatitis when assessing how well patients are responding to treatment.
An overview of topical and oral therapies used to treat mild-to-moderate atopic dermatitis.
December 14th 2021
Variables considered when developing and referring to treatment formularies for atopic dermatitis.
December 20th 2021
Dr Lio discusses features that make JAK inhibitors, including ruxolitinib, abrocitinib, baricitinib, and upadacitinib, attractive in the management of atopic dermatitis.
Drs Shah and Lio explore where topical ruxolitinib fits into therapeutic sequencing in atopic dermatitis, compared with oral JAK inhibitors.
January 4th 2022
An overview of limitations faced by payers and clinicians who play a role in the management of atopic dermatitis.